HBM9378 (SKB378/WIN378)
Asthma, COPD
Phase 1Active (Greater China)
Key Facts
About Harbour BioMed
Harbour BioMed is a publicly traded biotech (HKEX: 02142) with a mission to deliver breakthrough medicines through its innovative antibody technology platforms. The company has successfully transitioned from a technology licensor to a clinical-stage entity with a maturing pipeline, evidenced by multiple out-licensing deals and strategic collaborations with major pharmaceutical companies. Its 'global for global' strategy leverages R&D centers in the US, Europe, and China to build a diversified portfolio of novel therapeutics.
View full company profileTherapeutic Areas
Other Asthma, COPD Drugs
| Drug | Company | Phase |
|---|---|---|
| HP-Betadex DPI Formulations | Aquilon Pharmaceuticals | Clinical |
| Generic Advair (Fluticasone/Salmeterol) | Lupin Limited | ANDA Filed/Approved |
| Respiratory Inhalation Portfolio (Generic) | Cipla | ANDA Filed/Approved |
| Wixela Inhub (Fluticasone/Salmeterol) | Viatris | Launched |
| QX008N | Qyuns Therapeutics | Phase 1 |
| RELVAR/BREO ELLIPTA | Innoviva | Commercial |